VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-2.98%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$251M
AUM Growth
-$19M
(-7%)
Cap. Flow
-$3.64M
Cap. Flow
% of AUM
-1.45%
Top 10 Holdings %
Top 10 Hldgs %
7.1%
Holding
477
New
43
Increased
256
Reduced
137
Closed
41
Top Buys
| 1 |
The Mosaic Company
MOS
|
$900K |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$877K |
| 3 |
Enphase Energy
ENPH
|
$858K |
| 4 |
Gartner
IT
|
$732K |
| 5 |
Devon Energy
DVN
|
$727K |
Top Sells
| 1 |
L3Harris
LHX
|
$740K |
| 2 |
Cheniere Energy
CQP
|
$732K |
| 3 |
Agilent Technologies
A
|
$713K |
| 4 |
Copart
CPRT
|
$688K |
| 5 |
Equifax
EFX
|
$678K |
Sector Composition
| 1 | Healthcare | 18.83% |
| 2 | Real Estate | 17.55% |
| 3 | Materials | 12.77% |
| 4 | Financials | 9.88% |
| 5 | Energy | 9.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Harmony Biosciences
HRMY
$2.07B
| $235K | 0.09% |
5,296
+78
| +1% | +$3.46K |
|
302
Main Street Capital
MAIN
$5.95B
| $232K | 0.09% |
6,909
-4,368
| -39% | -$147K |
|
303
Nektar Therapeutics
NKTR
$764M
| $230K | 0.09% |
4,801
+70
| +1% | +$3.35K |
|
304
Moderna
MRNA
$9.78B
| $229K | 0.09% |
1,940
-5,173
| -73% | -$611K |
|
|
BCIC
305
BCP Investment Corporation Common Stock
BCIC
$160M
| $228K | 0.09% |
10,846
-2,085
| -16% | -$43.8K |
|
306
Amgen
AMGN
$153B
| $226K | 0.09% |
1,001
+16
| +2% | +$3.61K |
|
307
Relmada Therapeutics
RLMD
$54.8M
| $226K | 0.09% |
6,118
+50
| +0.8% | +$1.85K |
|
308
United Therapeutics
UTHR
$18.1B
| $226K | 0.09% |
1,077
+14
| +1% | +$2.94K |
|
|
SGEN
309
DELISTED
Seagen Inc. Common Stock
SGEN
| $223K | 0.09% |
1,630
+26
| +2% | +$3.56K |
|
|
INBX
310
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $220K | 0.09% |
12,263
+91
| +0.7% | +$1.63K |
|
311
Legend Biotech
LEGN
$6.66B
| $218K | 0.09% |
5,351
+77
| +1% | +$3.14K |
|
312
Caribou Biosciences
CRBU
$174M
| $215K | 0.09% |
20,369
+154
| +0.8% | +$1.63K |
|
313
Halozyme
HALO
$8.76B
| $214K | 0.09% |
5,400
+76
| +1% | +$3.01K |
|
314
Ironwood Pharmaceuticals
IRWD
$188M
| $213K | 0.08% |
20,570
+303
| +1% | +$3.14K |
|
315
Gossamer Bio
GOSS
$668M
| $210K | 0.08% |
17,496
+126
| +0.7% | +$1.51K |
|
316
Exelixis
EXEL
$10.2B
| $209K | 0.08% |
13,327
+194
| +1% | +$3.04K |
|
317
Ultragenyx Pharmaceutical
RARE
$3.07B
| $206K | 0.08% |
4,965
+70
| +1% | +$2.9K |
|
318
Roivant Sciences
ROIV
$8.82B
| $203K | 0.08% |
63,056
+927
| +1% | +$2.98K |
|
|
ITCI
319
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $203K | 0.08% |
4,357
+61
| +1% | +$2.84K |
|
|
ISEE
320
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $199K | 0.08% |
11,075
+78
| +0.7% | +$1.4K |
|
321
Monroe Capital Corp
MRCC
$164M
| $198K | 0.08% |
27,284
-2,888
| -10% | -$21K |
|
322
Oxford Square Capital
OXSQ
$172M
| $196K | 0.08% |
65,045
-8,869
| -12% | -$26.7K |
|
323
Geron
GERN
$893M
| $191K | 0.08% |
81,613
+597
| +0.7% | +$1.4K |
|
324
Kezar Life Sciences
KZR
$29.8M
| $191K | 0.08% |
2,214
+17
| +0.8% | +$1.47K |
|
325
Phathom Pharmaceuticals
PHAT
$875M
| $187K | 0.07% |
16,847
+121
| +0.7% | +$1.34K |
|